CD8是一种膜结合糖蛋白，广泛表达于细胞毒性T细胞（CD8+T细胞）、部分自然杀伤（NK）细胞及胸腺细胞发育阶段的特定群体上。它通常以α链和β链的异二聚体形式存在，作为T细胞受体（TCR）的共受体，与主要组织相容性复合体I类分子（MHC-I）结合，增强TCR与抗原肽-MHC复合物的亲和力，从而促进下游信号传导和T细胞激活。CD8在免疫应答中发挥关键作用，是机体清除病毒感染细胞和肿瘤细胞的重要效应分子之一。由于其在免疫调控中的核心地位，CD8成为肿瘤免疫治疗、免疫细胞研究及免疫调控机制探索中的重要靶点。
CD8 is a membrane-bound glycoprotein widely expressed on cytotoxic T cells (CD8⁺ T cells), certain subsets of natural killer (NK) cells, and specific populations during thymocyte development. It typically exists as a heterodimer of an alpha and a beta chain, functioning as a co-receptor for the T-cell receptor (TCR). It binds to Major...
CD8 is a membrane-bound glycoprotein widely expressed on cytotoxic T cells (CD8⁺ T cells), certain subsets of natural killer (NK) cells, and specific populations during thymocyte development. It typically exists as a heterodimer of an alpha and a beta chain, functioning as a co-receptor for the T-cell receptor (TCR). It binds to Major Histocompatibility Complex class I (MHC-I) molecules, enhancing the affinity of the TCR for the peptide-MHC complex, thereby promoting downstream signal transduction and T cell activation. CD8 plays a critical role in immune responses and is one of the key effector molecules for the body to clear virus-infected cells and tumor cells. Due to its central role in immune regulation, CD8 has become an important target in tumor immunotherapy, immune cell research, and the exploration of immune regulatory mechanisms.
根据2024年国家卫健委数据显示，我国成年人的超重率和肥胖率分别达到34.3%和16.4%，这意味着超过一半的成年人体重超标。肥胖是糖尿病、心血管疾病及多种癌症的重要风险因素。预计到2050年，全球超重和肥胖人数将占成人人口的半数以上。面对当前生活方式干预效果有限、现有药物存在副作用等治疗困境，开发新型、安全有效的抗肥胖策略迫在眉睫。
Data from the National Health Commission of China in 2024 shows that the overweight and obesity rates among Chinese adults have reached 34.3% and 16.4%, respectively, meaning more than half of the adult population is overweight. Obesity is a significant risk factor for diabetes, cardiovascular diseases, various cancers, and metabolic syndrome....
Data from the National Health Commission of China in 2024 shows that the overweight and obesity rates among Chinese adults have reached 34.3% and 16.4%, respectively, meaning more than half of the adult population is overweight. Obesity is a significant risk factor for diabetes, cardiovascular diseases, various cancers, and metabolic syndrome. It is projected that by 2050, over half of the global adult population will be overweight or obese. Faced with the limited effectiveness of current lifestyle interventions and the side effects of existing medications, the development of novel, safe, and effective anti-obesity strategies is urgently needed.
银屑病关节炎(PsA)是一种累及皮肤、关节、肌腱等多个组织的慢性炎症性疾病，严重限制患者的活动能力，并降低其生活质量与工作效率。传统改善病情抗风湿药(DMARDs)对部分患者效果有限，而现有传统单克隆抗体(mAb)生物制剂则因分子量过大(约150kDa)、组织穿透性差，难以有效分布于关节滑膜、肌腱等低血管化组织，导致滑膜液中药物浓度远低于血浆，无法充分发挥疗效。研究表明，仅约三分之一的患者在治疗6个月内能达到最小疾病活动度(MDA)。此外，PsA的发病与IL-17细胞因子家族密切相关，IL-17A和IL-17F在病灶组织中过度表达并形成同源/异源二聚体共同驱动炎症，仅抑制单一因子难以实现最佳治疗效果。因此，开发兼具双靶点抑制能力与高组织穿透性的新型抗体疗法，成为突破当前PsA治疗瓶颈的...
银屑病关节炎(PsA)是一种累及皮肤、关节、肌腱等多个组织的慢性炎症性疾病，严重限制患者的活动能力，并降低其生活质量与工作效率。传统改善病情抗风湿药(DMARDs)对部分患者效果有限，而现有传统单克隆抗体(mAb)生物制剂则因分子量过大(约150kDa)、组织穿透性差，难以有效分布于关节滑膜、肌腱等低血管化组织，导致滑膜液中药物浓度远低于血浆，无法充分发挥疗效。研究表明，仅约三分之一的患者在治疗6个月内能达到最小疾病活动度(MDA)。此外，PsA的发病与IL-17细胞因子家族密切相关，IL-17A和IL-17F在病灶组织中过度表达并形成同源/异源二聚体共同驱动炎症，仅抑制单一因子难以实现最佳治疗效果。因此，开发兼具双靶点抑制能力与高组织穿透性的新型抗体疗法，成为突破当前PsA治疗瓶颈的关键。